In rhabdomyosarcoma, fusion-positive subtypes show unique chromatin looping driven by the PAX3–FOXO1 oncoprotein40,42, offering a potential target for clinical interventions35,43. This evidence concerns the gene PAX3 and rhabdomyosarcoma.